Nuvation Bio, Inc. (NUVB) shares surged 5.13% in pre-market trading on Friday, following a series of positive analyst reports and price target increases. The biotechnology company's stock received a boost as multiple research firms expressed confidence in its future prospects.

RBC Capital Markets raised its price target on Nuvation Bio to $7 from $6, while maintaining an Outperform rating with a Speculative Risk assessment. This upward revision suggests growing optimism about the company's potential. Additionally, H.C. Wainwright reiterated its Buy rating on NUVB, setting an even more ambitious price target of $10 per share.

The positive sentiment is further reinforced by the overall analyst consensus. According to FactSet, Nuvation Bio currently has an average rating of Buy, with a mean price target of $8.14. This bullish outlook from Wall Street analysts appears to be driving investor enthusiasm, contributing to the stock's significant pre-market rally. As Nuvation Bio continues to develop its pipeline of oncology therapeutics, investors will be closely watching for further updates on the company's progress and any additional analyst recommendations.